Preliminary data indicates Sinovac COVID-19 vaccine effective against Brazilian P1 variant: official

Health News
FILE PHOTO: Healthcare workers wait before receiving the first dose of the Sinovac’s CoronaVac coronavirus disease (COVID-19) vaccine in the Positivo event center at the Barigui Park in Curitiba, Brazil January 28, 2021. REUTERS/Rodolfo Buhrer

BRASILIA/SAO PAULO (Reuters) – Preliminary data from a study in Brazil indicates that the COVID-19 vaccine developed by China’s Sinovac Biotech Ltd is effective against the P1 variant of the virus first discovered in Brazil, Sao Paulo’s state governor Joao Doria said on Wednesday.

Doria’s comments at a news conference in Sao Paulo confirm a Reuters report from earlier this week, which said the study had tested the blood of vaccinated people against the Brazilian variant of the virus. Coronavac, as the Sinovac shot is known, is the main vaccine currently being used to inoculate people in Brazil.

Dimas Covas, head of research institute Butantan, which is manufacturing the Sinovac vaccine, said other tests in China have indicated effectiveness against the UK and South Africa variants.

Butantan has already delivered 16 million doses of the vaccine to Brazil’s Ministry of Health, which has acquired 4 million doses from India of the Oxford-AstraZeneca vaccine.

Source: Read Full Article

Related posts:
  1. Brazil health ministry says plans to order 30 million more Coronavac doses
  2. COVID infections are dropping in North America, but vaccination too slow in Latin America, says PAHO
  3. valtrex withdrawl